Recombinant
RabMAb

Recombinant Anti-5T4 antibody [EPR5529] (ab134162)

Publishing research using ab134162? Please let us know so that we can cite the reference in this datasheet.

ab134162 has been referenced in 5 publications.

  • Pirie-Shepherd SR  et al. Detecting expression of 5T4 in CTCs and tumor samples from NSCLC patients. PLoS One 12:e0179561 (2017). PubMed: 28727782
  • Abdalla Z  et al. Loss of epithelial markers is an early event in oral dysplasia and is observed within the safety margin of dysplastic and T1 OSCC biopsies. PLoS One 12:e0187449 (2017). PubMed: 29216196
  • Guo X  et al. 5T4-specific chimeric antigen receptor modification promotes the immune efficacy of cytokine-induced killer cells against nasopharyngeal carcinoma stem cell-like cells. Sci Rep 7:4859 (2017). PubMed: 28687750
  • Kerk SA  et al. 5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 23:2516-2527 (2017). PubMed: 27780858
  • Sapra P  et al. Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells. Mol Cancer Ther 12:38-47 (2013). IHC-P . PubMed: 23223830

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up